eMS News

Earlier this month, the US Food and Drug Administration (FDA) approved alemtuzumab (Lemtrada, Genzyme, a Sanofi Company) for the treatment of relapsing forms of multiple sclerosis (MS). A company statement…

At the Education Summit, we opened the floor for Q & A for participants to ask questions related to the doctors presentations. The Q & A was recorded and we’ve…

People experiencing symptoms consistent with secondary-progressive multiple sclerosis may be eligible to participate in a clinical research trial of an investigational therapy, Siponimod.  A new Phase III clinical research trial,…

We recently chatted with one of our fantastic volunteers, Matt Tarpey. Matt was born and raised in Denver, Colorado. He was diagnosed with MS in 2008. He’s a big Broncos…

Last month neurologists from the Rocky Mountain MS Center joined 8,500 MS specialists who gathered in Boston to present findings on multiple sclerosis research. The Americas and European Committees for…

Poor adherence to medication regimens is a significant problem. According the World Health Organization, only 50 percent of patients worldwide who have chronic illnesses take their medication as it is…

Fiscal and Physical Interventions for Arthritis Sep 13, 2014 9:30 AM – 12:30 PM From the RMMSC: Our friends at the Arthritis Foundation – Colorado have extended an invitation to…

We’ve heard some remarkable stories during this month’s MS4MS campaign, and today we’re adding to the list. Meet Elizabeth Persons. She’s a runner, mountain biker, hiker and athlete who moved…

Participants Are Needed for an Exercise Study for People with Multiple Sclerosis Researchers from the Neurophysiology of Movement Laboratory on the University of Colorado Boulder campus and the Multiple Sclerosis…